ArticleMolecular psychiatry2022
A novel peripheral biomarker for depression and antidepressant response.
Article in Molecular psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 33 citations in OpenAlex.
- Molecular Signatures of Blood Biomarkers in Depression: Gene Expression Analysis ofDiagnostics (Basel, Switzerland) · 2026Article
- Adenylyl Cyclase 8 in Dorsal CA1 Neurons Prevents Depressive-Like Behaviors by Maintaining Neuronal Excitability and Glutamatergic Neurotransmission Through TIP39-PTH2R Signaling.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The science of psychedelic medicine.Nature medicine · 2026Review
- Conceptual analysis of mechanisms and methods in psychedelic clinical trial design: a narrative review.Therapeutic advances in psychopharmacology · 2026Review
- Rafting toward a depression biomarker.European archives of psychiatry and clinical neuroscience · 2025Article
- Early Brain Functional Connectivity Changes Induced by Antidepressants and Placebo.bioRxiv : the preprint server for biology · 2025Article
- A simple platelet biomarker is associated with symptom severity in major depressive disorder.Molecular psychiatry · 2025Article
- From Synaptic Plasticity to Neurodegeneration: BDNF as a Transformative Target in Medicine.International journal of molecular sciences · 2025Review
- An observational feasibility study on the impact of green exposure on major depressive episode symptomatology and inflammatory biomarkers.Frontiers in psychiatry · 2025Article
- A heterotrimeric G protein (Gsα) biomarker may predict antidepressant response in subjects with major depressive disorder.Frontiers in psychiatry · 2025Article
- Predicting depression severity using machine learning models: Insights from mitochondrial peptides and clinical factors.PloS one · 2025Article
- Shared and unique transcriptomic signatures of antidepressant and probiotics action in the mammalian brain.Molecular psychiatry · 2024Article
- FMOD Alleviates Depression-Like Behaviors by Targeting the PI3K/AKT/mTOR Signaling After Traumatic Brain Injury.Neuromolecular medicine · 2024Article
- Precision Medicine in Depression: The Role of Proteomics and Metabolomics in Personalized Treatment Approaches.Advances in experimental medicine and biology · 2024Review
- Erythrocyte Membrane Fatty Acid Composition as a Potential Biomarker for Depression.The international journal of neuropsychopharmacology · 2023Article
- Lipids in major depressive disorder: new kids on the block or old friends revisited?Frontiers in psychiatry · 2023Review
- Clinical Utility of Fluid Biomarker in Depressive Disorder.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2022Review
- A novel set of volatile urinary biomarkers for late-life major depressive and anxiety disorders upon the progression of frailty: a pilot study.Discover mental health · 2022Article
- The role of the type 7 adenylyl cyclase isoform in alcohol use disorder and depression.Frontiers in pharmacology · 2022Review
- GαFrontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
In contrast to healthy controls, the heterotrimeric G protein, Gsalpha (Gsα) is ensconced predominantly in lipid rafts in subjects with major depressive disorder (MDD) resulting in impaired stimulation of adenylyl cyclase. In this small proof-of-concept study, we examined the hypothesis that translocation of Gsα from lipid rafts toward a more facile activation of adenylyl cyclase is a biomarker for clinical response to antidepressants. There were 49 subjects with MDD (HamD
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.